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Background: Identifying genetic variants that lead to discernible phenotypes is the core of Mendelian genetics.
An approach that considers embryonic lethality as a bona fide Mendelian phenotype has the potential to reveal
novel genetic causes, which will further our understanding of early human development at a molecular level.
Consanguineous families in which embryonic lethality segregates as a recessive Mendelian phenotype offer a
unique opportunity for high throughput novel gene discovery as has been established for other recessive
postnatal phenotypes.
Results: We have studied 24 eligible families using autozygosity mapping and whole-exome sequencing. In addition to
revealing mutations in genes previously linked to embryonic lethality in severe cases, our approach revealed seven novel
candidate genes (THSD1, PIGC, UBN1, MYOM1, DNAH14, GALNT14, and FZD6). A founder mutation in one of these genes,
THSD1, which has been linked to vascular permeability, accounted for embryonic lethality in three of the study families.
Unlike the other six candidate genes, we were able to identify a second mutation in THSD1 in a family with a less severe
phenotype consisting of hydrops fetalis and persistent postnatal edema, which provides further support for the
proposed link between this gene and embryonic lethality.
Conclusions: Our study represents an important step towards the systematic analysis of “embryonic lethal genes”
in humans.Background
The in utero development of humans from a single-
celled zygote to a newborn with trillions of remarkably
diverse cells with three-dimensional organization as
organs is a highly complex process that remains in-
completely understood. Much of our understanding
of the molecular control of human development
comes from the discipline of developmental genetics.
The use of animal models as surrogates to under-
stand these molecular events by virtue of forward
and reverse genetics approaches that deconvolute these* Correspondence: falkuraya@kfshrc.edu.sa
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creativecommons.org/publicdomain/zero/1.0/complex events to the level of individual genes has been
helpful but does not obviate the need to study human
embryos.
In humans, the ability to trace certain birth defects to
individual genetic lesions has served as a “shortcut” to
accelerate the discovery of the genetic control of many
aspects of normal development. The premise of this
approach is that genes linked to birth defects must be
indispensable to the normal development of the respect-
ive organ(s), especially in the Mendelian context where
the link is directly causal. In fact, it can be argued that
the study of Mendelian forms of birth defects has pro-
vided the most compelling list of genes that are required
for normal human development [1].
Embryonic lethality is a well-studied phenomenon in
many model organisms, and the proportion of genes that
are indispensable to development is remarkable. Forss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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out [2]. A similar systematic survey has been more chal-
lenging to conduct in higher organisms but available
data suggest a lethal knockout phenotype for 30 % of
mouse genes in the homozygous state [3]. Since sys-
tematic knockout of each human gene to test its
viability cannot be done experimentally, naturally oc-
curring mutations that effectively knock out the re-
spective genes provide a practical alternative. Building
on the successful approach of using Mendelian genet-
ics of birth defects to understand normal morphogen-
esis of individual organs, we reckoned that Mendelian
forms of embryonic lethality offer a window into the
essential genetic components of early organismal de-
velopment in humans. In this study, we report our
genomic analysis of multiplex consanguineous pedi-
grees in which embryonic lethality appears to follow a
Mendelian recessive pattern. This approach revealed
known disease genes that have been reported to cause
embryonic lethality in severe cases, in addition to
genes that have not been previously linked to human
diseases, representing novel candidates. The candidacy
of one of these novel genes is further supported by
positional mapping data as well as the identification of
two different mutations.Consanguineous















Fig. 1 Workflow of the studyResults
Identification of Mendelian forms of embryonic lethality
We have identified 24 consanguineous families in which
two or more pregnancies were diagnosed with lethal
non-immune hydrops fetalis (NIHF; Figure S1 in
Additional file 1). High quality DNA was available from
at least one affected fetus in 19 of the 24 families
and these were subjected to whole-exome sequencing
(WES). Additional file 2 summarizes the raw data char-
acteristics from these 50× coverage exomes. This was
followed by gene discovery using the algorithm outlined
in Fig. 1 and detailed in Additional file 3. In seven of
these families, WES revealed a likely pathogenic variant
in a gene known to cause NIHF in severe cases (Table 1).
Family 13DG1635 had a homozygous truncating muta-
tion in CTSA, which predicts galactosialidosis, a known
cause of NIHF [4–6]. Similarly, families 14DG1727,
14DG1819, 13DG0042, 13DG2155, and 14DG0947 had
likely pathogenic mutations in GUSB as the only variants
that remained after applying the various filters. These
mutations predict GUSB-related mucopolysaccharidosis
VII, another established cause of NIHF in severe cases
[7, 8]. Family 13DG0975 was found to harbor a homozy-
gous stopgain mutation in NEB (c.21076C >T:p.R7026X),





Table 1 Summary of the variants identified by WES of families with recurrent fetal loss
Patient ID Variant remaining after WES filtering Effect of the mutation Relevance to embryonic lethality
14DG1727 GUSB:NM_000181:exon2:c.307C > T:p.R103W Replaces a highly conserved amino acid
(PolyPhen score 1; SIFT score 0)
Known cause of NIHF in
severe cases
14DG1819 GUSB:NM_000181:exon10:c.1586A > G:p.Y529C Replaces a highly conserved amino acid
(PolyPhen score 1; SIFT score 0)
Known cause of NIHF in
severe cases
10DG0827 CHRNA1:NM_001039523:exon7:c.762C > T:p.R254C Replaces a highly conserved amino acid
(PolyPhen score 1; SIFT score 0)
Known cause of NIHF in
severe cases
09DG01201 PIGC:NM_002642:exon2:c.659 T > C:p.L220P Replaces a highly conserved amino acid
(PolyPhen score 0.998; SIFT score 0.01)
Novel candidate
12DG2262 UBN1:NM_016936:exon14:c.2356 T > A:p.L786M Replaces a highly conserved amino acid
(PolyPhen score 0.915; SIFT score 0.02)
Novel candidate
13DG0042 GUSB:NM_000181:exon7:c.1144C > T:p.R382C Replaces a highly conserved amino acid
(PolyPhen score 0.995; SIFT score 0)
Known cause of NIHF in
severe cases
13DG0259 None - -
13DG0447 DNAH14:NM_001373:exon23:c.3755 T > A:p.M1252K Replaces a highly conserved amino acid
(PolyPhen score 0.805; SIFT score 0)
Novel candidate
13DG0806 THSD1:NM_018676:exon3:c.617G > A:p.C206Y Replaces a highly conserved amino acid
(PolyPhen score 0.999; SIFT score 0)
Novel candidate
13DG0975 NEB:NM_001164507:exon140:c.21076C > T:p.R7026X Truncation of >50 % of the protein Known cause of NIHF in
severe cases
13DG1635 CTSA:NM_000308:exon6:c.649delC:p.L217fs Truncation of >75 % of the protein
sequence
Known cause of NIHF in
severe cases
13DG1885 MYOM1:NM_003803:exon38:c.4987G > A:p.V1663M Replaces a highly conserved amino acid
(PolyPhen score 0.999; SIFT score 0)
Novel candidate
13DG2155 GUSB:NM_000181:exon3:c.398G > C:p.W133S, Replaces a highly conserved amino acid
(PolyPhen score 0.984; SIFT score 0)
Known cause of NIHF in
severe cases
14DG0052 FZD6:NM_001164616:exon5:c.773A > G:p.Y258C Replaces a highly conserved amino acid
(PolyPhen score 1; SIFT score 0)
Novel candidate
14DG0946 THSD1:NM_018676:exon3:c.617G > A:p.C206Y Replaces a highly conserved amino acid
(PolyPhen score 0.999; SIFT score 0)
Novel candidate
14DG0947 GUSB:NM_000181:exon7:c.1069C > T:p.R357X Truncation of >75 % of the protein sequence Known cause of NIHF in
severe cases
14DG1037 GALNT14:NM_024572:exon13:c.C1273T:p.R425X Truncation of >75 % of the protein sequence Novel candidate
14DG1695 THSD1:NM_018676:exon3:c.617G > A:p.C206Y Replaces a highly conserved amino acid
(PolyPhen score 0.999; SIFT score 0)
Novel candidate
14DG11738 THSD1:NM_018676:exon3:c.G670A:p.R224X Truncation of >75 % of the protein
sequence
Novel candidate
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Family 10DG0827 was also found to harbor a homo-
zygous mutation in the muscle-related gene CHRNA1
(c.762C > T:p.R254C) and we reported this family as
the first application of WES to identify the cause of
recurrent fetal loss in humans [10]. The candidate
causal variants in the remaining families, on the other
hand, involve genes that have not been previously linked to
human phenotypes, thus highlighting them as potential
candidates for embryonic lethality.
The single candidate variant that survived the various
filters in two of the remaining families was identical — a
missense mutation in THSD1 (c.617G > A:p.C206Y) —
and linkage analysis combining the two families revealed
a single linkage peak that overlaps with THSD1 (Fig. 2).Surprisingly, in family 13DG0806, the missense mutation
in THSD1 was also found in the homozygous state in
two siblings who are said to have had severe edema on
prenatal ultrasound and on postnatal examination but
that gradually resolved with age. Since this suggests that
THSD1 mutation can be compatible with an attenuated
phenotype, we decided to enroll two consanguineous
families in which NIHF was not associated with a lethal
outcome. In family 14DG1695, the mother presented
during pregnancy and her fetus had typical findings of
NIHF but gave history of two previous children with a
similar presentation who later improved spontaneously.
Sequencing of THSD1 in the fetus confirmed the pres-
ence of the same missense mutation. Unfortunately, this






















Fig. 2 a Pedigrees of the two families that generated linkage to THSD1 (index boxed in red). b Genome-wide linkage analysis showing a single
significant peak (red arrow) that spans the THSD1 locus. c Cartoon of the THSD1 gene and protein with the location of the two identified mutations
marked. The missense mutation replaces a highly conserved amino acid across species
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consanguineous family in which two siblings presented
with persistent lymphedema and have history of NIHF
during their pregnancies. Sequencing of THSD1 revealed
a homozygous truncating mutation (c.G670A:p.R224X;
Fig. 2; Figure S2 in Additional file 1). This variant has
been reported to be heterozygous in two individuals in
the ExAC browser (rs9536062) for an allele frequency of
0.00001648, which is compatible with this being a
disease-causing allele. Reassuringly, WES in these two
families independently revealed the same mutations by
applying the filters we used in the other study families.
In addition to THSD1, the candidate genes identified
in the remaining families have not been previously
linked to human diseases and thus represent novel can-
didates for embryonic lethality (PIGC, UBN1, DNAH14,
MYOM1, FZD6, and GALNT14).
Discussion
The spectrum of phenotypes associated with Mendelian
disorders is very wide, and embryonic lethality can be
viewed as the severe end of that spectrum [1]. It haslong been noted that embryonic lethality can be the pre-
senting feature of known Mendelian disorders in severe
cases. However, until recently it has not been possible
to study embryonic lethality as the “entry” phenotype
because the phenotype is usually too nonspecific to
guide testing. WES represents an exciting methodology
that bypasses this limitation since it targets the entire
coding genome regardless of the phenotype [10]. In
this study, we extended our experience in combining
the power of WES with autozygosity mapping for
determining the genetic causes of many recessive
Mendelian conditions in our highly consanguineous
population [11] to the study of embryonic lethality as
another recessive Mendelian condition in selected
families. Specifically, we targeted multiplex consan-
guineous families in which embryonic lethality likely
follows a recessive pattern. Our choice of lethal NIHF
was based on the longstanding experience with this
phenotype as the final common pathway of diverse
pathophysiological perturbations leading to fetal loss,
many of which are genetic in etiology, especially in re-
current cases [12].
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and CHRNA1 can be viewed as “positive controls” in
that they lend credence to the methodology used in this
study to identify the cause of embryonic lethality. These
genes are known to be mutated in established Mendelian
diseases (mucopolysaccharidosis, galactosialidosis, nema-
line myopathy and fetal akinesia, respectively) that
present as embryonic lethality in severe cases. On the
other hand, the genes identified in the other families
have not been previously linked to any Mendelian
phenotype so they represent novel candidate genes. In
the case of THSD1, it appears that mutations in this
gene cause a range of Mendelian phenotypes ranging
from a lethal form of NIHF to self-limited lymphedema
that resolves with age. For the other novel candidate
genes, their identification in one family each precludes
speculation on the range of phenotypes they may cause
besides the proposed link to embryonic lethality.
THSD1 is the most compelling candidate we identified
in this study in view of the linkage data and the identifi-
cation of two independent mutations. It encodes a
thrombospondin type 1 domain-containing protein of
poorly understood function. It was first identified in
2006 as a marker of primitive hematopoietic stem cells
and endothelial cells [13]. Recently, it has been proposed
that THSD1 has a potential role in angiogenesis and
maintenance of vascular integrity [14]. Thus, it is tempt-
ing to speculate that the mutations we identified in this
gene compromise vascular integrity resulting in a range
of phenotypes from embryonic lethality to persistent or
self-limiting edema as we observed in the families we
report in this study.
Unlike THSD1, however, the remaining novel genes
remain candidates since they were observed to be mu-
tated only once, and additional families will be required
to confirm their proposed link to embryonic lethality.
Nevertheless, available information on the function of
these genes and their involvement in basic cellular func-
tions appear suggestive. For example, PIGC encodes an
endoplasmic reticulum membrane protein required for
the first step of glycosylphosphatidylinositol (GPI) bio-
synthesis [15]. GPI is a major posttranslational modifica-
tion of many eukaryotic proteins to anchor them to
membranes. Disruption of GPI2 (the yeast homolog of
PIGC in human) is lethal in yeasts [16]. Similarly,
GALNT14 encodes an enzyme that catalyzes the first
step in the O-glycosylation of mammalian proteins by
transferring N-acetyl-D-galactosamine (GalNAc) to pep-
tide substrates. The homozygous truncating mutation
we identified in this gene will likely cause a severe form
of O-glycosylation disorder that may have resulted in
embryonic lethality in the respective family. It is worth
highlighting that disruption of the genes involved in this
pathway are lethal in yeast and mouse [17, 18]. Availableliterature supports the candidacy of the other candidate
genes as well. UBN1 encodes an essential component
of a chromatin remodeling complex that also includes
HIRA [19]. Intact UBN1 is required for HIRA
stabilization and proper localization, and HIRA−/− is
embryonic lethal in mouse [20, 21]. MYOM1 encodes
myomesin, a major binding partner of another sarco-
meric protein Titin, a major protein component of
striated muscles [22]. Homozygous deletion of the Titin
domain that interacts with myomesin results in embry-
onic lethality in mouse [23]. For the remaining genes,
there is insufficient evidence to support their potential
role in embryonic lethality.
Conclusions
Our study, to our knowledge, represents the first at-
tempt to systematically catalogue monogenic causes of
embryonic lethality in humans by combining WES and
autozygome analysis in selected families. The apparently
high yield of this approach in the study cohort justifies
future expansion to hundreds of similarly selected fam-




Families were enrolled in this study if parents were con-
sanguineous and had a history of at least two pregnan-
cies diagnosed with lethal forms of NIHF using standard
criteria used in maternal-fetal medicine. After signing
written informed consent, as part of an institutional review
board-approved research protocol in compliance with the
Declaration of Helsinki (KFSHRC RAC# 2080006 and
2121053), a blood sample from at least one affected fetus
was obtained from the umbilical cord and stored in EDTA
tubes for further analysis. Detailed morphological examin-
ation by ultrasonography and, when applicable, postnatal
clinical examination were recorded.
Autozygosity mapping
Determination of the autozygous genomic intervals
(autozygome) was achieved by using runs of homozygos-
ity (ROH) that are >2 Mb in size extracted from a
genome-wide genotyping array as described before [24].
Briefly, DNA extracted from whole blood was run on
Axiom SNP Chip platform following the manufacturer’s
instructions (Affymetrix) followed by ROH determin-
ation using AutoSNPa software [25].
Whole-exome sequencing
Exome capture was performed using TruSeq Exome
Enrichment kit (Illumina) following the manufacturer’s
protocol. Samples were prepared as an Illumina sequen-
cing library, and in the second step, the sequencing
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Illumina Exome Enrichment protocol. The captured li-
braries were sequenced using an Illumina HiSeq 2000
Sequencer. The reads were mapped against UCSC hg19
[26] by BWA [27]. The SNPs and Indels were detected
by SAMTOOLS [28].
Mapping of likely causal variants
Variants from WES were filtered such that only novel
(or very low frequency, 0.1 %), coding/splicing, homozy-
gous variants that are within the autozygome of the
affected fetus and are predicted to be pathogenic were
considered as likely causal variants [29]. Frequency of
variants was determined using publically available vari-
ant databases (1000 Genomes, Exome Variant Server
and ExAC) as well as a database of 560 in-house ethnic-
ally matched exomes. Pathogenicity was likely if the mu-
tation is loss-of-function (splicing/truncating) or, in the
case of missense/in-frame indels, removes a highly con-
served amino acid and is predicted to be pathogenic by
the two in silico prediction modules PolyPhen and SIFT.
All exomes described in this study can be accessed at [30].
Availability of supporting data
All novel variants in this study have been deposited
in ClinVar with the following accession numbers:
SCV000222665–SCV000222684. Access to the whole-
exome data used in this study is provided through the
TraBioS Data Warehouse [30].
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